Precision Radiation Therapy Sets New Survival Benchmark for Lung Cancer

The SWOG/NRG Oncology S1914 trial, the largest prospective SBRT study conducted to date, enrolled 417 patients across 146 institutions. The results demonstrate that precision radiation can be delivered reliably at scale, marking a major shift from previous standards where survival rates for inoperable cases often hovered below 40%. Dr. Charles B. Simone II, Chief Medical Officer at the New York Proton Center and co-first author of the study, emphasized that these findings provide a definitive new benchmark for clinical practice.

Researchers also evaluated the addition of atezolizumab immunotherapy to the radiation regimen, discovering it offered no survival benefit while simultaneously increasing toxicity. Patients receiving the combined therapy experienced a 12% rate of Grade 3 or higher adverse events, compared to only 3% for those treated with SBRT alone. Given the rigorous quality assurance protocols employed across the 146 participating sites, the data confirms that SBRT monotherapy remains the optimal standard of care for this patient population.